Market Overview

Global Plasma Fractionation Market size was valued at USD 36.49 Billion in 2023 and is poised to grow from USD 39.96 Billion in 2024 to USD 82.58 Billion by 2032, growing at a CAGR of 9.5% in the forecast period (2024-2032).

The Global Plasma Fractionation Market is becoming a growing sector in the healthcare and biotechnology industries as globally demand for plasma-derived therapies increases alongside awareness of its therapeutic potential. It is one of the key therapeutic agents in treating a wide variety of medical ailments such as immune deficiency, bleeding disorders, and problems involving critical care.

This market has also seen a lot of developments in technology and techniques regarding plasma fractionation, which have made the extraction and processing of plasma-derived products much more efficient and cost-effective. Such development has broadened the spectrum of possibilities in therapeutics and increased application areas for plasma fractionation services and products. Hence, healthcare institutions and pharmaceutical manufacturers are increasingly inclining to this form of plasma fractionation as an important valuable resource for the production of life-saving treatments.

The key market drivers include increasing cases of chronic diseases such as hemophilia and immunodeficiency disorders; also include liver disease, wherein patients undergo therapies derived from plasma. The growing older population affecting all the countries would mostly add demand to such plasma-related therapies because geriatric patients tend to encounter conditions needing plasma-based treatments. Furthermore, advances in diagnostic instruments and an increasing understanding of the human immune system have contributed significantly in widening the application confines of plasma-derived therapies, even for autoimmune diseases and neurological disorders.

The Plasma Fractionation Market indeed enjoys the impetus of many promising investments in research and development undertaken by pharmaceutical firms in an effort to innovate and improve and expand the current therapies. The market is likely to register a consistent pace of growth, as the widening margin of therapeutic indications for and increase in safety and efficiency of plasma-derived products auger well for the industry. This growth reinforces the collective responsibility of regulatory frameworks assuring safety and quality of plasma products while raising awareness regarding the advantages of plasma-based therapies among health care professionals and patients alike.

Challenging high costs of plasma fractionation, problems with the supply of plasma, and the complexities of maintaining quality control over production processes are top points on the list of considerations. But even in such a scenario, continued growth for the Global Plasma Fractionation Market is almost guaranteed with improvements in technology and rising requirements for health care, which will lead to the facilitation of life-saving therapies derived from plasma.

Market Drivers

Increasing Demand for Plasma-Derived Therapies

• Increasing prevalence of chronic diseases and rare conditions in need of therapies beyond conventional drugs has considered into the increased demand for plasma-derived therapies, such as immunoglobulins, clotting factors, and albumin, which are fundamental in treating hemophilia, immunodeficiency disorders, liver diseases. These therapies often provide healthy living function in managing these diseases and make them integral to modern health care.
• This demand has increased greatly owing to the rapid aging of world population-age in increasing the number of older people, but in all cases, older individuals acquire various health physical conditions that will be in need of long-term treatments, and hence will be classified as critical care conditions.
• Patients are starting to grasp the need for these plasma-derived treatments on the part of healthcare professionals and patients, hence the need will continue to rise. Increased personalization and target treatments give even more charm to the plasma-derived products as they are tailored-bespoke treatments tailored to the patients' needs. Disease prevalence, aging population, and therapeutic applications are merging to stimulate the continued expansion of end-user demand for plasma-derived therapies worldwide.

Key Findings:

• The U.S. FDA extended the approval of Octapharma AG's plasma-based medication, wilate (von Willebrand Factor/Coagulation Factor VIII Complex), in December 2023. The regular prophylaxis included in the revised extended approved label is intended to lower the incidence of bleeding episodes in adults and children six years of age and older.
• The U.S. FDA approved Grifols, S.A.'s new immunoglobulin (Ig) purification and filling factory in North Carolina in November 2023. The company was able to produce an extra 16 million grams of plasma treatment every year thanks to this facility.
• Grifols, S.A. opened a production plant in Marburg, Germany, in March 2023, with increased capacity to produce human plasma treatments.
• Takeda Pharmaceutical Company Limited invested USD 764.6 million in March 2023 to construct a new production facility for plasma-derived therapies in Osaka, Japan. When the plant opens in 2030, the company's manufacturing capacity in Japan will have increased fivefold.

Growing Healthcare Awareness and Access to Plasma-Based Treatments

• Increased public awareness related to healthcare and access to plasma process treatment has promoted the market access for plasma fractionation. Nevertheless, with the evolving healthcare system internationally, there arises an increasing consensus concerning the life-saving ability of therapies derived from plasma. Thus, with time, patients and health professionals learn more about the treatment that will benefit them to varying degrees for many conditions, including immune deficiencies, bleeding disorders, and situations of critical care failure. The realization on the part of the patients leads to a greater number of patients seeking a cure with plasma-based therapies as viable alternatives for chronic and rare conditions.
• At the same time, the improvement of healthcare infrastructure and policies in regional development is improving access to these therapies. The capacity of many healthcare facilities to store and process plasma is beginning to improve, and growing initiatives to enhance plasma donation make it even more accessible. The treatments based on the plasma are becoming widely available to a more significant patient population. Increased access is also supported by the growing presence of global pharmaceutical companies with healthcare providers, ensuring that plasma-derived products are available to a broader demographic.
• The combination of awareness and improved access will help the demand and subsequently allow the Plasma Fractionation Markets to grow. The market will keep continuing to expand as many people learn about plasma-derived therapies and availability associated with the healthcare systems increases.

Market Opportunities

Development of Novel Therapies for Autoimmune and Neurological Diseases

• New innovative therapeutic approaches for autoimmune and neurological diseases are robustly emerging in the Plasma Fractionation Market. In this regard, plasma therapies have proven to be useful to a certain extent to cure diseases that are usually very difficult to cure, such as autoimmune diseases (lupus, multiple sclerosis, etc.) and neurological diseases (Guillain-Barré syndrome, Alzheimer's disease, etc.), where the body's immune response attacks its own tissues or neurons. It causes chronic inflammation, nerve damage, and many debilitating impacts. Interestingly, plasma therapies, especially immunoglobulins and other immune-modulating proteins, have been garnering a lot of attention in terms of their potential efficacy in regulating immune responses and reducing inflammation-an entirely novel approach to the management of these complex disorders.
• The extraction and concentration of a specific fraction of plasma proteins, targeted treatments could be developed, thereby providing the potential for improved disease management and even better patient outcomes than at present. Further refinements will be focused on these therapies to improve their efficiency and to extend their applications to other neurological and autoimmune conditions. In addition, advancement in personalized medicine offers the possibility of developing therapies specific for each individual, elevating plasma-derived treatments even more in challenge-prone diseases.
• With better understanding and understanding of the pathogenesis of autoimmune and neurological diseases and the establishment of new therapeutic mechanisms, the plates for plasma-derived therapies would grow in size in the very near future. This novel treatment not only improves the treatment paradigm for such patients; it also opens a new market opportunity for the plasma fractionation industry.

Market Restraining Factors

Risk of Contamination and Safety Concerns

• The risks of contamination and safety concerns continue to be a very important issue in the Plasma Fractionation Market. Plasma, with a biological nature, may met infection from various pathogenic agents, including viruses, bacteria, and other microbial agents. Even though modern screening and testing protocols have vastly improved the risks of infection transmitted through plasma-derived therapies, contamination during collection, storage, and processing is always possible. This has serious implications, as contaminated plasma has the potential for serious consequences to health in patients, including HDV, hepatitis B, and hepatitis C.
• Strict regulation and advanced purification techniques were applied to minimize these risks in the fractionation process. However, all this complexity and cost is huge in ensuring that products of plasma are safe. Quality lapses or failure to meet standards of safety may lead to contamination casualties, which in turn damage the reputation of manufacturers and healthcare providers, not to mention the harm done by these cases to patients. Further, the potential for occurrence of allergic reactions or adverse effects in patients administered with plasma-derived therapies adds a further dimension of concern that requires ongoing monitoring and quality assurance.
• These safety concerns remain, although technology has diminished them greatly, as it is still a factor affecting the market in terms of growth and expansion while necessitating continued innovation, regulation vigilance, and public confidence in the safe application of plasma-based therapies.

Segmentation Analysis

The market scope is segmented because of by Product, by Application, by End-user.

• By Product

Based on the Product of the market is segmented into Albumin, Immunoglobulin (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin), Coagulation Factors (Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others), Protease Inhibitors, Others.

Product segments in the Global Plasma Fractionation Market include Immunoglobulins, which especially place emphasis on Intravenous Immunoglobulin (IVIg). This has become the most important and fastest-growing segment because these therapies play a very important role in treating diverse conditions affecting human beings, such as immune deficiencies, autoimmune diseases, and neurological disorders. They are used widely in the treatment of primary and secondary immunodeficiencies, and in conditions such as Guillain-Barré syndrome, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy (CIDP). The action of immunoglobulins has established for them an important place in present-day healthcare for rare and complex diseases because the benefits of administration, as seen, are immune-modulatory, anti-inflammatory, and protective against infection.

There is a healthy share of demand of Immunoglobulins from the increasing number of patients emerging across the globe with autoimmune diseases or immunodeficiencies which necessitate durable therapies. Recognition of the benefits of immunoglobulin therapies in several therapeutic areas and increasing healthcare access and awareness has also boosted the superiority of this segment over others.

• By Application

Based on the Application of the market is segmented into Immunology & Neurology, Hematology, Critical Care, Pulmonology, Others.

Within The various applications for the Plasma Fractionation Market, the Immunology and Neurology section has been the most dominant. This is because plasma-derived therapies have been found to have important roles in treating various immune disorders and neurological disorders. Immunoglobulins, for example, are derived from plasma products and are used for the treatment of immunodeficiencies and autoimmune disorders like primary immunodeficiency, multiple sclerosis, and Guillain-Barré syndrome, among others. These therapies have been quite effective in the modulation of the immune system and in reducing inflammation; they cannot be missed in the caring of chronic, often debilitating conditions.

More prevalent neurological conditions due to the aging of populations and better diagnosis, plus this use of plasma-derived immunoglobulins repurposed to study possible therapeutic outcomes in various more conditions associated with the nervous system have marked a period of growth in this segment. The demand for such therapies at present is high, supporting Immunology & Neurology's dominance in the market; as more autoimmune diseases and neurological diseases are being realized as treatable through plasma-based treatments, the patients are expected to increase.

• Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA. North America has secured the lead in global plasma fractionation owing to its well-settled healthcare infrastructure, advanced medical technologies and high rate of inclination towards plasma therapy in the region. The U.S. basically is said to be the most significant player in this dominance by being home to a substantially large patient population who could use plasma-based treatments for hemophilia, immune deficiencies and even neurological disorders. It is to be noted that the healthcare system in this region is well-developed, giving its patients access to sophisticated treatment and therapies, thus leading to an increase in utilization of plasma-derived products. In addition, there also strong regulatory framework in place so as to ensure safety and quality of any plasma products, which in turn drives market growth along with how people view plasmas. Presence of major pharmaceutical and biotechnology players, focusing mainly in the field of plasma fractionation development, further strengthens North America's position.

This region also has a well-developed plasma collection and donation infrastructure, allowing supply of raw materials for its fractionation process. From the growing research and development activities in the field of immunology and neurology, more plasma-derived therapies are realized and further add to the already existing dominance of this region.

This region is foreseen to be the most rapidly increasing part of the Global Plasma Fractionation Market. These factors include the increased healthcare infrastructure, rising burden of chronic illnesses, and increased accessibility to healthcare in these countries such as China, India, and Japan. The demand for plasma-derived medicines is expected to rise as the population of the region ages and masses learn much about illnesses that will require plasma-based therapies.

List of Companies Profiled

• Grifols S.A.
• CSL Limited
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion S.p.A
• LFB S.A.
• Biotest AG
• Sanquin
• Bio Products Laboratory Ltd.
• Intas Pharmaceuticals Ltd

Key Industry Developments

• The foundation for a deal with Kedrion for the full commercialization and distribution of Biotest AG's immunoglobulin product, Yimmugo, in the United States was laid in July 2024. This follows the FDA's clearance of Yimmugo's Biologic License Application (BLA).
• Takeda declared in January 2024 that Immune Globulin Infusion 10% solution, an intravenous immunoglobulin treatment, has received FDA approval to improve neuromuscular dysfunction and disability in adults with chronic inflammatory demyelinating polyneuropathy.
• Shilpa Medicare Limited finished the Phase 1 clinical trial for recombinant human albumin 20% in August 2023.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Plasma Fractionation Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Global Ammonia Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Ammonia market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Ammonia. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Ammonia companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Ammonia Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Ammonia Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S.
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 12 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

• To gain insightful analyses of the Ammonia market and have comprehensive understanding of the global market and its commercial landscape.
• Assess the production processes, major issues, and solutions to mitigate the development risk.
• To understand the most affecting driving and restraining forces in the market and its impact in the global market.
• Learn about the Ammonia market strategies that are being adopted by leading respective organizations.
• To understand the future outlook and prospects for the Ammonia market. Besides the standard structure reports, we also provide custom research according to specific requirements.

Research Scope of Ammonia Market

• Historic year: 2019- 2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million